Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
16.8M
-
Number of holders
-
19
-
Total 13F shares, excl. options
-
649K
-
Shares change
-
+242K
-
Total reported value, excl. options
-
$2.68M
-
Value change
-
+$952K
-
Number of buys
-
13
-
Number of sells
-
-5
-
Price
-
$4.11
Significant Holders of Elicio Therapeutics, Inc. - Common Stock, par value $0.01 per share (ELTX) as of Q2 2024
23 filings reported holding ELTX - Elicio Therapeutics, Inc. - Common Stock, par value $0.01 per share as of Q2 2024.
Elicio Therapeutics, Inc. - Common Stock, par value $0.01 per share (ELTX) has 19 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 649K shares
of 16.8M outstanding shares and own 3.86% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (226K shares), ARMISTICE CAPITAL, LLC (100K shares), GEODE CAPITAL MANAGEMENT, LLC (71.5K shares), CM Management, LLC (50K shares), Arena Investors LP (50K shares), Hudson Bay Capital Management LP (48.7K shares), STATE STREET CORP (21.9K shares), BlackRock Inc. (19K shares), MEYER HANDELMAN CO (13.9K shares), and BRIDGEWAY CAPITAL MANAGEMENT, LLC (12.5K shares).
This table shows the top 19 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.